Libtayo could capture up to $1 billion in sales from the NSCLC category, according to analysts, although additional upside is possible if an ongoing combination study yields positive results.

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945’s potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

One patient with Merkel cell carcinoma (MCC) achieved a durable complete response with 15 milligrams per kilogram (mg/kg) solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...